When Will Big Pharma Join the EV Party?

• Examining the key barriers limiting Big Pharma investment and participation in the exosome therapeutics landscape
• Evaluating the impact of regulatory uncertainty, manufacturing challenges, clinical validation requirements, and commercial considerations on adoption decisions
• Identifying the scientific, clinical, and business milestones needed to transition exosome therapeutics into a mainstream pharmaceutical modality

Speakers:

Christopher Paradise

Senior Vice President, Research & Development

Rion

Dilip Moonka

Medical Director, Liver Transplantation

Henry Ford Health System

Susan Drapeau

Senior Principal, Regenerative Medicine

Dark Horse Consulting Group

Joseph Barendt

Senior Director, International Business Development

Daicel Life Sciences